All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

CHMP Recommends Capivasertib/Fulvestrant for Pretreated ER+/HER2– Advanced Breast Cancer With PIK3CA, AKT1, or PTEN Alterations

April 29th 2024

The EMA’s CHMP recommended capivasertib/fulvestrant for ER-positive, HER2-negative advanced breast cancer harboring PIK3CA, AKT1, or PTEN alterations.

Florida Cancer Specialists & Research Institute Clinical Research Driving Progress to Cure Cancer

April 29th 2024

Clinical research conducted at Florida Cancer Specialists & Research Institute, LLC was highlighted at the 2024 AACR Annual Meeting.

FDA Approves Trastuzumab-strf for HER2-Overexpressing Breast and Gastric/GEJ Cancer

April 29th 2024

The FDA has approved trastuzumab-strf for HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or GEJ adenocarcinoma.

Mainstreaming of Genetic Testing Is Tied to Increased Testing Rates in Ovarian Cancer

April 29th 2024

Ying Liu, MD, MPH, and Tiffany Sia, MD, discuss the benefits of mainstreaming genetic testing in patients with ovarian cancer.

MRI-Guided Neoadjuvant Chemotherapy Could be Used in HR-/HER2+ Breast Cancer

April 28th 2024

MRI-guided treatment could be used to optimize the duration of neoadjuvant chemotherapy in hormone receptor-negative/HER2-positive breast cancer.

Understanding Chemotherapy-Related Clonal Hematopoiesis in Ovarian Cancer

April 27th 2024

Sara Corvigno, MD, PhD, expands on an analysis that uncovered the CHIP variants that occurred at a higher frequency in patients with ovarian cancer post-chemotherapy.

Garje Elucidates Biomarker-Driven Approaches Generating Excitement in Metastatic Prostate Cancer

April 26th 2024

Rohan Garje, MD, highlights advances made in precision medicine approaches for the management of metastatic prostate cancer.

Toxicities Hinder Potential Efficacy of Ceritinib/Trametinib in Pretreated Advanced Melanoma

April 26th 2024

Zeynep Eroglu, MD, discusses how findings from a phase 1/2 study of ceritinib and trametinib could help inform future research in melanoma.

Comparable Germline Variant Rates Seen Across Racial Groups in Metastatic Prostate Cancer

April 26th 2024

Kara N. Maxwell, MD, PhD, discusses the prevalence of germline mutations in racially diverse cohorts of patients with metastatic prostate cancer.

Frontline Amivantamab Plus Chemo Receives Positive EU CHMP Opinion for EGFR Exon 20 Insertion+ NSCLC

April 26th 2024

Frontline amivantamab with chemotherapy has been recommended for approval by the CHMP in EGFR exon 20 insertion+ non–small cell lung cancer.

Fox Chase Cancer Center Welcomes Dr Simon Sung

April 26th 2024

Fox Chase Cancer Center is pleased to announce the hiring of Simon Sung, MD, as an associate professor in the Department of Pathology.

CHMP Recommends Frontline Nivolumab Plus Chemo in Unresectable/Metastatic Urothelial Carcinoma

April 26th 2024

Frontline nivolumab plus chemotherapy has been recommended for approval in unresectable or metastatic urothelial carcinoma.

Fruquintinib Receives Positive CHMP Opinion for Previously Treated mCRC

April 26th 2024

CHMP has voiced its support for the approval of fruquintinib in previously treated metastatic colorectal cancer.

Navigating Personalized Approaches With Radiation Therapy for Early-Stage Breast Cancer

April 26th 2024

Robert W. Mutter, MD, discusses personalized treatment approaches with radiation and endocrine therapy in early-stage breast cancer.

DENALI Study Seeks to Prove Efficacy of Azenosertib in High-Grade Serous Ovarian Cancer

April 26th 2024

The phase 2 DENALI trial is investigating azenosertib in patients with high-grade serous ovarian cancer.

Decreasing Grade 3/4 Infections, Limited Hospitalizations Underscore Potential for Linvoseltamab in R/R Myeloma

April 25th 2024

Sundar Jagannath, MBBS, discusses linvoseltamab and expands on key efficacy and safety findings from the LINKER-MM1 trial in patients with relapsed/refractory multiple myeloma.

More Than 25% of Cancer Survivors Report Significant Levels of Disability After Cancer Diagnosis, According to New Study

April 25th 2024

A survey of cancer survivors found that over a quarter had a physical disability impairing mobility and almost 10% had a disability affecting self-care.

ODAC Decisions Confirm Benefit of Ide-Cel and Cilta-Cel in Earlier Line R/R Myeloma Therapy

April 25th 2024

Kenneth C. Anderson, MD, discusses the recent ODAC decisions for ide-cel and cilta-cel, highlighting clinical trial data supporting the indications.

Next-Generation ColoAlert Screening Test Shows High Sensitivity, Specificity for CRC and Adenoma Detection

April 25th 2024

Topline findings with the next-generation ColoAlert® test demonstrated 92% sensitivity and 90% specificity rates for colorectal cancer detection.

Vebreltinib Receives NMPA Approval in China for MET Fusion+ Glioma

April 25th 2024

Vebreltinib has received approval from China’s NMPA in pretreated IDH-mutant, PTPRZ1-MET fusion–positive astrocytoma or glioblastoma.